human immunoglobulin G + Placebo
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Dermatomyositis
Conditions
Dermatomyositis
Trial Timeline
Oct 21, 2019 → Dec 2, 2024
NCT ID
NCT04044690About human immunoglobulin G + Placebo
human immunoglobulin G + Placebo is a phase 3 stage product being developed by CSL for Dermatomyositis. The current trial status is terminated. This product is registered under clinical trial identifier NCT04044690. Target conditions include Dermatomyositis.
What happened to similar drugs?
0 of 2 similar drugs in Dermatomyositis were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04044690 | Phase 3 | Terminated |
Competing Products
14 competing products in Dermatomyositis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| tacrolimus | Astellas Pharma | Pre-clinical | 26 |
| M5049 high dose + Placebo | Merck | Phase 2 | 27 |
| BAF312 + Placebo | Novartis | Phase 2 | 27 |
| MEDI7734 + Placebo | Amgen | Phase 1 | 29 |
| Etanercept + Placebo | Amgen | Phase 1 | 29 |
| Dazukibart | Pfizer | Phase 3 | 47 |
| Anti-Beta Interferon (PF-06823859) | Pfizer | Phase 2 | 35 |
| PF-06823859 low + Placebo Arm + PF-06823859 high | Pfizer | Phase 2 | 35 |
| Tofacitinib | Pfizer | Phase 1 | 29 |
| Emapalumab | Swedish Orphan Biovitrum | Phase 2 | 42 |
| Empasiprubart IV | Argenx | Phase 2 | 36 |
| GLPG3667 + Placebo | Galapagos | Phase 2 | 33 |
| Lenabasum 20 mg + Lenabasum 5 mg + Placebo | Corbus Pharmaceuticals | Phase 3 | 30 |
| JBT-101 + Placebo | Corbus Pharmaceuticals | Phase 2 | 17 |